InflaRx reports first Phase IIa data for IFX-1 in sepsis

InflaRx GmbH (Jena, Germany) said IFX-1 demonstrated "biological proof of concept" as a treatment for sepsis and met the primary endpoints in the German Phase IIa SCIENS trial. The double-blind, placebo-controlled study enrolled 72 patients suffering from early septic organ dysfunction.

The company said primary endpoints included safety and pharmacodynamics/pharmacokinetics, and that IFX-1 significantly reduced complement 5a (C5a). ...